Get the Stockscreener App
3.74
3.89%
0.14
After Hours:
3.74
Scpharmaceuticals Inc stock is traded at $3.74, with a volume of 346.90K.
It is up +3.89% in the last 24 hours and down -10.95% over the past month.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
See More
Previous Close:
$3.60
Open:
$3.62
24h Volume:
346.90K
Relative Volume:
0.98
Market Cap:
$186.40M
Revenue:
$17.63M
Net Income/Loss:
$-57.71M
P/E Ratio:
-2.812
EPS:
-1.33
Net Cash Flow:
$-60.45M
1W Performance:
+11.31%
1M Performance:
-10.95%
6M Performance:
+6.55%
1Y Performance:
-32.00%
1-Day Range:
$3.5536
$3.815
1-Week Range:
$3.28
$3.815
52-Week Range:
$3.075
$6.71
Scpharmaceuticals Inc Stock (SCPH) Company Profile
Name
Scpharmaceuticals Inc
Sector
Industry
Phone
617-517-0730
Address
25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA
Compare SCPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCPH
Scpharmaceuticals Inc
|
3.74 | 186.40M | 17.63M | -57.71M | -60.45M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Scpharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | Craig Hallum | Buy |
| Dec-01-22 | Initiated | Cowen | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Oct-11-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-02-22 | Initiated | Maxim Group | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Oct-15-19 | Initiated | H.C. Wainwright | Buy |
| Jan-30-19 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
View All
Scpharmaceuticals Inc Stock (SCPH) Latest News
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Bought by Rubric Capital Management LP - MarketBeat
scPharmaceuticals (STU:2SX) Cash Flow from Operations : €-64.68 Mil (TTM As of Sep. 2024) - GuruFocus.com
scPharmaceuticals (STU:2SX) Float Percentage Of Total Shares Outstanding : 88.47% (As of Nov. 21, 2024) - GuruFocus.com
scPharmaceuticals (STU:2SX) Intrinsic Value: Projected FCF : €-6.70 (As of Nov. 21, 2024) - GuruFocus.com
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless - Simply Wall St
Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term - Simply Wall St
HC Wainwright Expects Reduced Earnings for scPharmaceuticals - MarketBeat
King Luther Capital Management Corp's Strategic Acquisition in s - GuruFocus.com
Earnings Update: scPharmaceuticals Inc. (NASDAQ:SCPH) Just Reported And Analysts Are Trimming Their Forecasts - Yahoo Finance
500: Something went wrong - Investing.com India
SCPH stock touches 52-week low at $3.24 amid market challenges - Investing.com
scPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2024 Earnings Call Transcript - Insider Monkey
scPharmaceuticals Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
The one-year earnings decline has likely contributed toscPharmaceuticals' (NASDAQ:SCPH) shareholders losses of 33% over that period - Simply Wall St
Earnings call: scPharmaceuticals reports robust Q3 growth, eyes FDA nod By Investing.com - Investing.com UK
ScPharmaceuticals, Inc. (SCPH) Reports Q3 Loss, Lags Revenue Estimates - MSN
scPharmaceuticals Inc (SCPH) Q3 2024 Earnings Call Highlights: R - GuruFocus.com
scPharmaceuticals Inc (SCPH) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
scPharmaceuticals Reports Strong Growth in Q3 2024 - TipRanks
ScPharmaceuticals Q3 Loss Widens, Revenue Rises - Marketscreener.com
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
scPharmaceuticals' FUROSCIX Revenue Surges 164% YoY to $10M in Q3, Expands FDA Approval | SCPH Stock News - StockTitan
Certain Common Stock of scPharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2024. - Marketscreener.com
scPharmaceuticals (SCPH) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 - The Manila Times
scPharmaceuticals Sets Q3 2024 Earnings Call for November 13 | SCPH Stock News - StockTitan
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
KING LUTHER CAPITAL MANAGEMENT CORP Expands Stake in scPharmaceu - GuruFocus.com
TD Cowen reiterates Buy rating on scPharmaceuticals stock, highlights optimism for Furoscix approval - Investing.com India
TD Cowen reiterates Buy rating on scPharmaceuticals stock, highlights optimism for Furoscix approval By Investing.com - Investing.com South Africa
Third Time's The Charm For ScPharma? - RTTNews
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024 - GlobeNewswire
Congestive Heart Failure Treatment Market 2034: Clinical - openPR
The Attractiveness of Investing In scPharmaceuticals Inc (SCPH) is Growing - Knox Daily
Daily Progress: scPharmaceuticals Inc (SCPH) Drop -2.33, Closing at 3.97 - The Dwinnex
scPharmaceuticals GAAP EPS of -$0.41 misses by $0.05, revenue of $3.8M beats by $0.38M - MSN
Does scPharmaceuticals (SCPH) Have the Potential to Rally 291.9% as Wall Street Analysts Expect? - MSN
351,806 Shares in scPharmaceuticals Inc. (NASDAQ:SCPH) Acquired by Bank of Montreal Can - MarketBeat
scPharmaceuticals Inc. (NASDAQ:SCPH) Short Interest Down 15.0% in September - MarketBeat
Holdings of scPharmaceuticals Inc (SCPH) are aligned with the stars - SETE News
Craig Hallum gives a Buy recommendation for scPharmaceuticals Inc (SCPH) - Knox Daily
King Luther Capital Management Corp Purchases 752,005 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - MarketBeat
Investors in scPharmaceuticals (NASDAQ:SCPH) have unfortunately lost 23% over the last year - Yahoo Finance
Rice Hall James & Associates LLC Has $2.16 Million Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) - MarketBeat
scPharmaceuticals Inc [SCPH] Investment Guide: What You Need to Know - Knox Daily
scPharmaceuticals Inc. (NASDAQ:SCPH) Stock Holdings Increased by AIGH Capital Management LLC - MarketBeat
scPharmaceuticals Inc [SCPH] 10% Owner makes an insider purchase of 500,000 shares worth 2.0 million. - Knox Daily
scPharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
scPharmaceuticals’ $125 Million Senior Secured Term Loan - Global Legal Chronicle
Do investors need to be concerned about scPharmaceuticals Inc (SCPH)? - US Post News
There is no way scPharmaceuticals Inc (SCPH) can keep these numbers up - SETE News
Scpharmaceuticals Inc Stock (SCPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):